ArticleCancer discovery2018
Registry-linked trialAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07220239 (Menstrual Cup-based Endometrial Collection as an Alternative to Endometrial Biopsy in Lynch Syndrome Patients), which is not on this map. Cited by 379 papers.
0numbers the graph read from it
0cells of the map it votes in
379citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Menstrual Cup-based Endometrial Collection as an Alternative to Endometrial Biopsy in Lynch Syndrome Patients
Who cites it
379 citing papers in PubMed.
- Construction and application of mammary and breast cancer organoids.Cell insight · 2026Review
- Making the Case for Organ-on-Chip Platforms in Long-Acting Therapeutics Development.Advanced healthcare materials · 2026Review
- Review
- Anti-PD-1 Treatment Restores Effector Function in Exhausted-like T Cells from Malignant Ascites of Ovarian Cancer Patients.Cancers · 2026Article
- Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration.Journal of translational medicine · 2026Review
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
- EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.bioRxiv : the preprint server for biology · 2026Article
- Bladder cancer organoids: bridging pathological features and drug response for precision oncology.International urology and nephrology · 2026Review
- Effects of TBK1 genetic polymorphisms and their interactions with hepatitis B virus mutations on the risk of hepatocellular carcinoma in Han Chinese population: a case-control study.International journal of surgery (London, England) · 2026Article
- Patient-specific lung cancer tumoroids recapitulate the tumor microenvironments for functional evaluation of therapeutic responses and immune-stromal interactions.Journal of translational medicine · 2026Article
- An immunocompetent bone marrow-on-a-chip model for studying human hematological malignancies and preclinical therapeutic screening.Nature protocols · 2026Review
- B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.Journal of experimental & clinical cancer research : CR · 2026Article
- Application of organoid models in basic and translational research of lung cancer: a narrative review.Translational lung cancer research · 2026Review
- A review of organoid-immune co-culture platforms to model the immune microenvironment of hepatocellular carcinoma and guide immunotherapy.Journal of translational medicine · 2026Review
- Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.Journal for immunotherapy of cancer · 2026Article
- Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response.Journal for immunotherapy of cancer · 2026Article
- Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.Nature communications · 2026Article
- Meningioma microenvironment harbors a rich immune landscape that evolves with biological state.Neuro-oncology · 2026Article
- Engineering Organ-on-a-Chip Systems for Cancer Immunotherapy: Strategies and Assay Integration.Bioengineering (Basel, Switzerland) · 2026Review
319 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
84 authors.
Russell W JenkinsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Amir R ArefDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Patrick H LizotteDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Elena IvanovaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Susanna StinsonGilead Sciences, Foster City, California.
Chensheng W ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michaela BowdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jiehui DengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hongye LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Diana MiaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
William WalkerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gao ZhangMelanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.
Tian TianDepartment of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
Chaoran ChengDepartment of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
Zhi WeiDepartment of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
Sangeetha PalakurthiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mark BittingerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hans VitzthumDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Jong Wook KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ashley MerlinoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Max QuinnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Chandrasekar VenkataramaniGilead Sciences, Foster City, California.
Joshua A KaplanGilead Sciences, Foster City, California.
Andrew PortellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Prafulla C GokhaleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bart PhillipsGilead Sciences, Foster City, California.
Alicia SmartDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Asaf RotemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Robert E JonesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lauren KeoghDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Maria AnguianoCenter for Applied Medical Research, University of Navarra, Pamplona, Spain.
Lance StapletonGilead Sciences, Foster City, California.
Zhiheng JiaGilead Sciences, Foster City, California.
Michal Barzily-RokniDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Israel CañadasDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tran C ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Marc R HammondDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Raven VlahosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eric S WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hua ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shuai LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Glenn J HannaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wei HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mai P HoangDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Adriano PirisDepartment of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Jean-Pierre ElianeDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Anat O Stemmer-RachamimovDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Lisa CameronConfocal and Light Microscopy Core Facility, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mei-Ju SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Parin ShahDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Benjamin IzarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Manisha ThakuriaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nicole R LeBoeufDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Guilherme RabinowitsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Viswanath GundaDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Sareh ParangiDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
James M ClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brian C MillerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shunsuke KitajimaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Rohit ThummalapalliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Benchun MiaoDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Thanh U BarbieDepartment of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Vivek SivathanuDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Joshua WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
William G RichardsDivision of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Raphael BuenoDivision of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Charles H YoonDepartment of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Juan MiretDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Meenhard HerlynMelanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.
Levi A GarrawayDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Paul T KirschmeierDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jochen H LorchDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
F Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Keith T FlahertyDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Roger D KammDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Genevieve M BolandDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Kwok-Kin WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
David DornanGilead Sciences, Foster City, California. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.
Cloud Peter PaweletzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MTuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9MTUMOR DEVELOPMENT AND PROGRESSION IN HUMAN MELANOCYTESP01CA025874 · NCI · WISTAR INSTITUTE · PI MARMORSTEIN, RONEN · 1985 to 2015
$19.0MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MMOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTargeting the cytokine circuitry of KRAS-driven lung cancerR01CA190394 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2015 to 2026
$4.5MMETASTATIS: BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPYR01CA047159 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1989 to 2015
$3.9MDevelopment of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint BlockadeU01CA214381 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BARBIE, DAVID A, KAMM, ROGER D · 2017 to 2021
$3.5MNCI NIH HHS P01 CA025874NCI NIH HHS P01 CA114046NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA047159NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA149738NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA190394NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA214381NIGMS NIH HHS T32 GM008313
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Agents, ImmunologicalCell Culture TechniquesCell Line, TumorCytokinesDrug Resistance, NeoplasmFlow CytometryHumansImmunohistochemistryImmunophenotypingMiceMicrofluidic Analytical TechniquesProgrammed Cell Death 1 ReceptorSpheroids, CellularTime-Lapse ImagingTumor Cells, CulturedAntineoplastic Agents, ImmunologicalCytokinesProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07220239ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.